Regenxbio Inc (RGNX)

Payables turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Cost of revenue (ttm)	US$ in thousands	137,951	137,678	136,222	136,832	146,534	148,063	154,183	148,644	133,201	111,133	111,921	103,915	98,968	95,847	69,820	64,914	57,879	54,573	48,685	41,671
Payables	US$ in thousands	22,786	21,859	11,639	23,283	27,213	25,210	16,985	24,708	11,387	19,845	9,354	11,311	10,622	15,244	10,901	9,008	6,409	9,608	5,851	4,204
Payables turnover		6.05	6.30	11.70	5.88	5.38	5.87	9.08	6.02	11.70	5.60	11.97	9.19	9.32	6.29	6.40	7.21	9.03	5.68	8.32	9.91

December 31, 2023 calculation

Payables turnover = Cost of revenue (ttm) ÷ Payables
= $137,951K ÷ $22,786K
= 6.05

Regenxbio Inc's payables turnover ratio has shown fluctuations over the past eight quarters, ranging from a low of 1.63 in Q4 2023 to a high of 3.73 in Q2 2022. A higher payables turnover ratio indicates that the company is paying off its suppliers more quickly, which could be a sign of efficient working capital management.

The significant spike in Q2 2023, with a payables turnover ratio of 3.35, suggests that the company was able to settle its payables at a much faster rate during that period. However, this spike could also be a result of one-time events or changes in the company's payment terms with suppliers.

Overall, it is important for Regenxbio Inc to monitor its payables turnover ratio consistently to ensure that it strikes the right balance between managing its cash flow effectively and maintaining good relationships with its suppliers.